Over the year, ALFI participates in numerous consultations issued by European Institutions and industry associations.
ALFI response to ESMA discussion papers of 19 December on guidelines on key concepts of the AIFMD and draft regulatory technical standards on types of AIFMs- ALFI statements
ALFI comments on Financial Stability Board Consultative Document - Strengthening Oversight and Regulation of Shadow Banking- ALFI statements
ALFI’s reply to the EC Consultation Document on UCITS product rules, liquidity management, depositary, money market funds and long term investments- ALFI statements
Please see ALFI's response here.
The UCITS IV Simplified Notification Procedure sub-working group has been monitoring the implementation of the UCITS IV Directive’s notification provisions since 2009 and has established a list of practical questions related to both the outward passporting and the inward passporting of UCITS to and from Luxembourg.
ALFI RESPONSE TO ESMA’s CONSULTATION PAPER ON GUIDELINES ON THE TREATMENT OF REPURCHASE AND REVERSE REPURCHASE- ALFI statements
Please view ALFI’s response here.
On 28 June 2012 ESMA published a consultation paper on guidelines on sound remuneration policies under the AIFMD.
The European Parliament issued on August 14th, 2012, a draft report of MEP Saïd El Khadraoui on Shadow Banking. ALFI’s position paper on this draft report focuses on the matters that are of particular relevance for the industry.
ALFI comments on ESMA’s consultation on its technical standards for the Regulation on OTC Derivatives, CCPs and Trade Repositories- ALFI statements
The European Securities and Markets Authority (ESMA) launched on June 25th a consultation on its technical standards under the Regulation on OTC derivatives, central counterparties and trade repositories (EMIR), which is aimed at improving the functioning of OTC derivatives markets in the European Union (EU).
On 27 June 2012 ALFI responded to IOSCO’s Consultation report on principles for the regulation of Exchange Traded Funds.
To read ALFI's response please click here
Appendice 1 - SB-Risks (UCITS & MMF)
Appendice 2 - SB Risks (AIFMD)